[Emphysematous pyelonephritis in a non-diabetic patient with a kidney tumour].

Ugeskr Laeger

Urologisk Afdeling, Roskilde Sygehus, Køgevej 7-13, 4000 Roskilde.

Published: March 2015

Emphysematous pyelonephritis (EPN) is a potentially life-threatening infection, where gas produced by bacteria accumulates in the kidney and the surrounding tissue. Although EPN usually presents in diabetic women, it is also associated with urinary tract obstruction and kidney tumours in non-diabetic patients. We present a case of EPN in a non-diabetic patient with a known kidney tumour, successfully treated with double-J catheter, antibiotics and delayed nephrectomy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

non-diabetic patient
8
patient kidney
8
[emphysematous pyelonephritis
4
pyelonephritis non-diabetic
4
kidney
4
kidney tumour]
4
tumour] emphysematous
4
emphysematous pyelonephritis
4
pyelonephritis epn
4
epn life-threatening
4

Similar Publications

Research conducted in India has shown that there is a high prevalence of non-diabetic kidney disease (NDKD) among Indian patients. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as potential treatments for preventing the progression of chronic kidney disease to advanced stages, regardless of their anti-diabetic effects. Dapagliflozin, which has been approved by the Central Drugs Standard Control Organization, is the SGLT2i drug class approved for use in both DKD and NDKD patients.

View Article and Find Full Text PDF

To decrease the number of chronic kidney disease (CKD), early diagnosis of diabetic kidney disease is required. We performed invariant information clustering (IIC)-based clustering on glomerular images obtained from nephrectomized kidneys of patients with and without diabetes. We also used visualizing techniques (gradient-weighted class activation mapping (Grad-CAM) and generative adversarial networks (GAN)) to identify the novel and early pathological changes on light microscopy in diabetic nephropathy.

View Article and Find Full Text PDF

Little is known about the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on atherosclerosis. We aimed to determine if a 90-day intake of Dapagliflozin could improve atherosclerosis biomarkers (namely endothelial function assessed by flow-mediated dilatation [FMD] and carotid intima-media thickness [CIMT]) in diabetic and non-diabetic acute coronary syndrome (ACS) patients when initiated in the early in-hospital phase. ATH-SGLT2i was a prospective, single-center, observational trial that included 113 SGLT2i naive patients who were admitted for ACS and who were prescribed Dapagliflozin at a fixed dose of 10 mg during their hospital stay for either type 2 diabetes or for heart failure.

View Article and Find Full Text PDF

The aim of this study was to examine the association between homocysteine (Hcy), uric acid (UA) and type 2 diabetes mellitus (T2DM), and to explore whether there was an interaction between Hcy and UA in the development of T2DM. A total of 1250 diabetic patients and 1250 non-diabetic controls were included in this case-control study. Binary logistic regression and interaction analysis were used to evaluate the association between Hcy, UA, and T2DM, and the combined effects of Hcy and UA on T2DM, respectively.

View Article and Find Full Text PDF

Background: Maintenance hemodialysis (MHD) is an effective treatment for patients with end-stage renal disease. Although MHD can prolong the survival of patients, their quality of life is lower and the fatality rate is higher. This work analyzed the factors related to the autogenous arteriovenous fistula (AVF)-like expansion of non-diabetic MHD patients by vascular ultrasound (VUS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!